Two major subtypes of cardiac β-adrenergic receptors (β−ARs) modulate the effects of catecholamines on excitation-contraction coupling. The predominantly G s -coupled β 1 -AR is evenly distributed across the sarcolemma and stimulates
T he cyclic nucleotides, cAMP and cGMP, are ubiquitous second messengers, which regulate cardiomyocyte function by acting in discrete subcellular microdomains. In particular, it has been proposed that such microdomains are based on differentially localized receptors, cAMP-dependent protein kinases, its anchoring proteins, and cAMP/cGMP hydrolyzing enzymes phosphodiesterases involved in termination and spatial confinement of cyclic nucleotide signaling.
1,2 cGMP can regulate compartmentalized cAMP signaling by either stimulating phosphodiesterase 2 or inhibiting phosphodiesterase 3 activity. 3, 4 However, because of the lack of real-time imaging techniques, cyclic nucleotide dynamics in distinct functionally relevant microdomains of adult cardiomyocytes and their role in disease are not well understood.
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far-reaching cAMP signals, which strongly increase contractility and promote cardiac remodeling. In contrast, the β 2 -AR couples to both G s -and G i -proteins and is exclusively located in transverse-tubules, thereby generating highly localized cAMP responses, which may protect from apoptosis and pathological remodeling. 5, 6 cGMP has been reported as a cardioprotective second messenger, because stimulation of cGMP production or inhibition of its degradation by cGMP-phosphodiesterase inhibitors leads to a reduction of β-AR-stimulated pathological hypertrophy. 7 Conversely, genetic deletion of the atrial natriuretic peptide (ANP) or brain natriuretic peptide receptor guanylyl cyclase A (GC-A) promotes cardiac hypertrophy. 8, 9 One well-established hallmark of chronic cardiac disease is the dramatic reduction of β 1 -AR densities, 10 its desensitization and a decrease of GC-A activity. 11 However, little is known about changes in microdomain-specific cAMP/cGMP signaling in diseased cardiomyocytes, especially not at disease onset, which is most relevant for therapeutic interventions.
Here, we show that during early cardiac hypertrophy and contrary to expectation, ANP augments catecholamine-stimulated force of single myocyte contraction and heart rates in intact hearts and in vivo. Using a novel transgenically expressed Förster resonance energy transfer (FRET)-based cAMP biosensor, we uncover that this is caused by a spatial redistribution of phosphodiesterase 2/3 between the β 1 -and β 2 -ARassociated microdomains without any change of whole-cell phosphodiesterase expression and activities. This represents a novel adaptation mechanism which may compensate early disease-driven changes and transiently support contractile function during pressure overload before the transition to decompensated chronic disease.
Methods
Detailed Methods section is in the Online Data Supplement.
FRET-Based cAMP Measurements in Cardiomyocytes
Adult mouse ventricular myocytes were freshly isolated and subjected to FRET measurements as described. 12 
Transverse Aortic Constriction
All animal experiments were performed according to the institutional and governmental guidelines as described. 13 Mice were euthanized 8 weeks after surgery for ventricular cardiomyocyte isolation or wholeheart measurements.
Statistics
Normal distribution was tested by the Kolmogorov-Smirnov test. Differences were analyzed using OriginPro8.6 software (OriginLab, Northampton) and 1-way ANOVA or Mann-Whitney tests, followed by Bonferroni post hoc test. Data are presented as mean±SE from the indicated number of independent experiments (animals and cells) per condition.
Results

ANP Increases Contractility in Hypertrophied Cardiomyocytes and Hearts
ANP has previously been found not to affect the isoproterenol-stimulated contractility of single healthy mouse ventricular cardiomyocytes.
14 Accordingly, ANP did not significantly change sarcomere shortening after submaximal isoproterenol stimulation of healthy cells ( Figure 1A and 1C) . However, in cardiomyocytes isolated from hearts after transverse aortic constriction (TAC), ANP applied after isoproterenol but not alone strikingly led to a significant positive inotropic response ( Figure 1B and 1C) . This effect could be mimicked by a cell-permeable cGMP analogue cGMP-AM but not by the selective NPR-C (clearance) receptor agonist cANP(4-23) (Online Figure IA , Online Data Supplement), suggesting that it is modulated by the GC-A/cGMP pathway. Interestingly, the stimulatory effect of ANP was observed also in Langendorffperfused intact TAC hearts where it could further increase the beating rate after isoproterenol prestimulation ( Figure 1D ). This finding could be also confirmed by hemodynamic measurements in vivo, where ANP augmented isoproterenol-induced increase of heart rate and showed a strong tendency for an increased cardiac output ( Figure 1E and 1F) . Remarkably, the ANP-stimulated cGMP levels were not reduced in TAC cells (Online Figure IB) , suggesting the absence of GC-A desensitization. This behavior of hypertrophied cardiomyocytes, which is in contrast to well-established β-AR and ANP receptor desensitization 11, 15 and absence of ANP effect on contractility occurring in chronic heart failure 16, 17 might indicate both early and specific disease-associated changes in cGMP-/ cAMP-dependent signaling. To study these changes in more detail, we performed real-time imaging of cAMP.
FRET Imaging Reveals Altered Subtype-Specific β-AR-cAMP Responses in Diseased Cardiomyocytes
Because membrane receptor-associated cAMP microdomains have been shown to regulate functional contractile responses, we sought to monitor cAMP dynamics directly in specific membrane compartments. To achieve this goal, we generated a novel transgenic mouse, which expresses a cAMP sensor pmEpac1 targeted to caveolin-rich sarcolemmal microdomains (Online Figure II) . Importantly, the sensor transgenic mice were indistinguishable from their control littermates in terms of heart function and cell size, showing no adverse cardiac phenotype (Online Figure III) . Side-by-side comparison with the previously described cytosolic otherwise identical version of the same biosensor (Epac1-camps) revealed that pmEpac1 showed slightly lower affinities to cAMP but could much better resolve local β 2 -AR cAMP signals (Online Figure IV) , which are known to compartmentalize close to transverse-tubular membranes. 6 After TAC, pmEpac1 mice showed increased heart size and wall thickness with only slightly reduced functional parameters, indicative of a relatively mild, functionally still compensated phenotype of pathological hypertrophy, which was accompanied by a 2-fold increase of plasma ANPlevels (Online Figure V) . In isolated cardiomyocytes, the localization of the FRET sensor in the striation-associated transverse-tubular membranes and surface sarcolemma was virtually unchanged (Online Figure VIA and VIB). First, we tested whether ANP has any effect on subsarcolemmal cAMP levels under the same experimental conditions as in Figure 1 . We prestimulated TAC and sham myocytes with a low dose of isoproterenol (3 nmol/L) and next applied 100 nmol/L of ANP. Indeed, ANP led to augmentation of isoproterenol-stimulated cAMP levels exclusively in TAC cells (Figure 2A and 2B). To further test how cAMP levels are affected at saturating β-AR agonist concentrations and which receptor subtypes are involved, we compared β 1 -and β 2 -AR specific responses in TAC versus sham cells and found significantly enhanced global isoproterenol responses, which were because of stronger β 1 -AR signals ( Figure 2C , 2D, and 2F). In contrast, β 2 -ARstimulated cAMP (β 2 -AR cAMP) responses were significantly reduced in diseased cells ( Figure 2E and 2F). These changes of β-AR-cAMP signals were not because of altered β-AR densities (164±16 versus 128±17 fmol/mg membrane protein in sham versus TAC cells, not significant, P=0.1, n=3) or β 1 -/β 2 -AR ratio, as confirmed by radioligand binding studies (Online Figure VIC) . In contrast to TAC cardiomyocytes, cells isolated from pmEpac1 hearts with a more severe heart failure phenotype established 12 weeks after myocardial infarction showed marked downregulation of β 1 -AR-cAMP signaling with unchanged β 2 -AR responses (Online Figure VII) .
In Hypertrophy, cGMP-Sensitive Phosphodiesterases Redistribute Between β 1 -AR-Associated and β 2 -AR-Associated Membrane Microdomains
We next studied the effects of various phosphodiesterase inhibitors after global and β 2 -AR-selective receptor stimulations in healthy cells. We found that although the β 1 -AR-cAMP microdomain is mostly controlled by phosphodiesterase 4 (followed by less active phosphodiesterase 3 and phosphodiesterase 2), the β 2 -AR-cAMP microdomain is under predominant control of phosphodiesterase 3, which was not detectable using the cytosolic FRET sensor Epac1-camps (Online Figure VIII) . The new membrane localized pmEpac1 sensor revealed that in diseased cells, phosphodiesterase 2 effects after global β 1 -AR stimulation were significantly reduced, whereas phosphodiesterase 3 and 4 inhibitor responses remained unchanged ( Figure 3A-3C ). In contrast, the predominant regulation of β 2 -AR-cAMP by phosphodiesterase 3 in this microdomain was abolished. Instead, the phosphodiesterase 2 effects were significantly increased, whereas phosphodiesterase 4 effects remained unchanged ( Figure 3D-3F ). These findings suggest a redistribution of phosphodiesterase 2 from the β 1 -AR to the β 2 -AR-associated microdomains and a selective downregulation of phosphodiesterase 3 in the β 2 -AR compartment. To test whether the disease leads to changes in physical localization of phosphodiesterase 2 and 3, we stained the cells with phosphodiesterase family-specific antibodies and analyzed the degree of their colocalization with α-actinin. Interestingly, TAC led to measurable alterations in subcellular phosphodiesterase 2 and 3 distribution (Online Figure IX) . Furthermore, relocalization of phosphodiesterase 2 between β 1 -AR and β 2 -AR microdomains could be observed in neonatal rat cardiomyocytes expressing affinity-tagged receptors (Online Figure  X) . Subcellular fractionation of sham and TAC heart revealed a movement of phosphodiesterase 2 from β 1 -AR-associated noncaveolar into β 2 -AR-containing caveolar fractions in disease, whereas phosphodiesterase 3 proportion in caveolinpositive fractions was reduced (Online Figure XI) . These data directly support our hypothesis that altered phosphodiesterase 2/3 inhibitor effects indeed arise from subcellular relocalization of these phosphodiesterases. Previously, it has been shown that under advanced cardiac hypertrophy, phosphodiesterases 3 and 4 activities are downregulated in rodent and human cardiomyocytes, 18,19 whereas phosphodiesterase 2 activity (which is a crucial phosphodiesterase for the regulation of submembrane ANP/GC-A/cGMP pools) 20 is increased in various heart failure settings, albeit not under compensated hypertrophy. 21 Strikingly, in our compensated mouse hypertrophy model, total phosphodiesterases 2 to 4 activities were unchanged (Online Figure XIIA) . Likewise, net expression levels of phosphodiesterase 2 analyzed by immunoblotting with whole-cell lysates were unaltered (Online Figure XIIB ). In addition, protein levels of the phosphodiesterase 4D8 isoform, which directly interacts with β 1 -AR, 22 or of β-arrestin 2, which recruits phosphodiesterases to the β 2 -AR, and of the functionally-relevant 3-isobutyl-1-methylxanthine-insensitive phosphodiesterase 8A 23 were also unaffected (Online Figure XIIC) . Collectively, these data indicate an early subcellular remodeling of phosphodiesterases and a switch between 2 cGMP-regulated phosphodiesterases in the β 2 -AR microdomain, that is, increase in local cGMP-stimulated phosphodiesterase 2 and a decrease in cGMP-inhibited phosphodiesterase 3 activities, occurring without any change of global phosphodiesterase activity and content at the cellular level. Interestingly, using immunoblot analysis we could detect a disease-associated shift of phosphodiesterase 3A isoforms from the primarily expressed phosphodiesterase 3A2 to the longest phosphodiesterase 3A1 isoform (Online Figure  XIII) , which is localized predominantly at sarcoplasmic reticulum instead of the plasma membrane. 24 Another potential mechanism of different phosphodiesterase localization might be an altered expression of scaffolding proteins, 1 of which AKAP13 (AKAP-Lbc) was increased, whereas PI3γ kinase was unchanged in our disease model (Online Figure XIII) .
cGMP-Dependent Regulation of β 2 -AR-cAMP Signals Is Altered in Hypertrophy
To study whether the altered balance between phosphodiesterases 2 and 3 in hypertrophy contributes to the cGMP-dependent regulation of cAMP levels in the β 2 -AR microdomain, we measured the effect of ANP in TAC and sham pmEpac1 cardiomyocytes after selective β 2 -AR stimulation. Addition of ANP could further enhance the β 2 -AR-prestimulated cAMP levels in healthy cells, which was because of cGMP-mediated phosphodiesterase 3 inhibition, because this effect was abolished in the presence of the phosphodiesterase 3-selective inhibitor cilostamide ( Figure 4A and 4B). In diseased cardiomyocytes, the ANP effect on β 2 -AR-cAMP levels was dramatically reduced. However, pretreatment of cells with Figure 4C and 4D) , suggesting that in cardiac hypertrophy, the redistribution of phosphodiesterases 2 and 3 inverses the cGMP-mediated effects on the β 2 -AR-cAMP pool. The described cGMP-dependent effects on β 2 -AR-cAMP did also directly translated into Figure XIV and of the cGMP-AM effect (100 μmol/L) under the same conditions, mean±SE, number of cells and P values for significant differences are indicated above the bars. F, Schematic representation of the proposed molecular switch mechanism. Redistribution of phosphodiesterase 2 from the β 1 -to the β 2 -AR-associated membrane microdomains leads to a decrease of the local β 2 -AR-cAMP and to an increase of global β 1 -AR-cAMP pool under elevated ANP and cGMP levels observed in early disease. The switch of β 2 -AR-associated phosphodiesterase 2 and 3 leads to a turnaround of cGMP/cAMP cross-talk between the β 2 -and β 1 -AR-associated microdomains, through which elevated ANP augments β-adrenoceptor-stimulated contractility under shifted β 1 -/β 2 -AR-cAMP balance. NE indicates norepinephire, the physiological β-AR agonist. FRET indicates Förster resonance energy transfer; and IBMX, blocker 3-Isobutyl-1-methylxanthine.
cell contractile responses (Online Figure XIVA and XIVB and Figure 4E ), which were exactly the opposite to the increased contractility after ANP application in TAC cells under global β-adrenergic stimulation (described in Figure 1 ), further supporting the idea of phosphodiesterases 2 and 3 redistribution between receptor-associated microdomains. Interestingly, cGMP-AM, which directly acts on these redistributed phosphodiesterases, could also here recapitulate the effect of ANP. Therefore, the observed changes of local cAMP levels monitored by FRET are directly translated into contractile response, specifically shifting the ANP-mediated effect on β-adrenoceptor-stimulated contractility from the β 2 -AR to the β 1 -AR associated compartment.
Discussion
In this study, we directly monitored compartmentalized effects of cAMP and cGMP on cell function in early cardiac disease and uncovered unexpected positive inotropic and chronotropic effects of ANP after β-AR stimulation. These changes are in sharp contrast to the well-documented β-AR and ANP receptor desensitization occurring in late-stage cardiac disease, such as heart failure. 11, 15 Real-time monitoring of cAMP using a novel mouse model expressing the targeted pmEpac1 FRET biosensor demonstrates functional redistribution of phosphodiesterase 2 and 3 between the β 1 -AR and β 2 -ARassociated membrane microdomains. This redistribution leads to switching of cGMP/cAMP cross-talk from the ANP/cGMP/ phosphodiesterase 3-mediated cAMP increase to an ANP/ cGMP/phosphodiesterase 2-mediated cAMP decrease after β 2 -AR stimulation, and exactly the opposite effect after β 1 -AR stimulation ( Figure 4F ). Functionally, not only does this lead to a change in physiologically less relevant β 2 -AR-specific contractile effects, but strikingly also to stimulatory ANPeffects on global contractile force after β-AR stimulation in hypertrophied myocytes. This effect is apparently caused by a shift in β 1 /β 2 -AR signal balance toward β 1 -AR signaling. Mechanistically, ANP-mediated potentiation of β-AR inotropic response at this stage of disease originates from the reorganization of microdomain-specific phosphodiesterase activity patterns that cause a shift of ANP-driven cAMP augmenting effect from local (β 2 -AR) toward global (β 1 -AR) cAMP pools. Unlike pronounced β 1 -AR/cAMP and ANP/cGMP signal desensitization in advanced heart failure, our model of early cardiac hypertrophy provides insights into molecular changes, which take place during the onset of chronic cardiac disease. Although these changes seem rather neutral with regard to the whole-cell phosphodiesterase activities, yet we show that even slight changes in local phosphodiesterase contributions can cause drastic changes in compartmentalized signaling patterns that directly translate into vastly different contractile effects of the same ligand, such as ANP (see Figure 1B and 1C and 4F). Importantly, the disease-relevant GC-A ligands natriuretic peptides ANP and brain natriuretic peptide are present at higher levels in systemic circulation during hypertrophy, and thus can directly activate cGMP production by not yet desensitized GC-A, thereby generating higher cardiomyocyte cGMP levels and affecting cGMP/cAMP cross-talk to modulate contractility.
Pathophysiologically, this effect might represent a compensatory mechanism to meet the enhanced demand on cardiac output under pressure overload. Strikingly, during early disease, the β 2 -AR, which generally plays a minor role in catecholamine-induced inotropic response, generates an important signaling microdomain, which can be regulated by either phosphodiesterase 2 or phosphodiesterase 3 to exert opposite effects on global β-AR-mediated contractility by the altered functional balance between the β 1 -and β 2 -AR signaling compartments. In this case, an additive effect of both β-AR subtypes on contractile force at healthy state may transform into a relation of reciprocal interdependence (contractile response≈β 1 -AR-cAMP/β 2 -AR-cAMP) in hypertrophy.
In summary, we uncovered a new adaptation mechanism in early cardiac disease, which involves subcellular redistribution of cGMP-regulated phosphodiesterases. We propose that such alterations well precede well-known cellular remodeling, which occurs during decompensated hypertrophy and heart failure associated with changed whole-cell phosphodiesterase activities and the desensitization of the β 1 -AR/cAMP and ANP/cGMP signaling cascades. This mechanism might become a new target for therapeutics acting on natriuretic peptides and microdomain-specific signaling in early disease.
• Cyclic nucleotides, cAMP and cGMP, play crucial role in regulating cardiac contractile function by acting in discrete subcellular microdomains.
• Chronic decompensated cardiac disease, such as heart failure, is associated with attenuated cAMP and cGMP signaling from β-adrenergic (β-AR) and natriuretic peptide receptors, respectively. • The role of cyclic nucleotide microdomains in cardiac disease is poorly understood, especially not at an early functionally compensated stage, which is most relevant for therapeutic interventions
What New Information Does This Article Contribute?
• A novel transgenic mouse, which expresses a highly sensitive Förster resonance energy transfer-based cAMP biosensor targeted to caveolin-rich membrane microdomains.
• In contrast to chronic disease, early cardiac hypertrophy is associated with an augmenting effect of the atrial natriuretic peptide (ANP) on β 1 -AR induced force (in vitro) and frequency (in vitro and in vivo) of contraction because of a redistribution of cGMP-regulated phosphodiesterases 2 and 3 between the β 1 -and β 2 -AR-associated membrane microdomains.
• This remarkable effect of ANP is brought about exclusively by subcellular, microdomain-specific alterations of phosphodiesterase localization and activity, while their whole-cell expression levels and β-AR densities are not yet altered at this stage of disease.
In this work, we sought to study the role of cyclic nucleotide microdomains in early cardiac disease. We generated novel transgenic mice expressing a highly-sensitive membrane-targeted Förster resonance energy transfer biosensor for cAMP and subjected these animals to transverse aortic constriction to induce compensated cardiac hypertrophy. In sharp contrast to welldocumented β-AR and ANP receptor desensitization occurring in chronic disease, we uncovered a positive inotropic effect of ANP in isolated myocytes and its positive chronotropic effect in isolated hearts and in vivo, which augmented β 1 -AR effects because of a redistribution of therapeutically relevant cGMP-regulated phosphodiesterases between the β 1 -and β 2 -AR-associated membrane microdomains. These subcellular alterations were not yet accompanied by whole-cell changes in phosphodiesterase activities and β-AR densities but already affected contractility, indicating a new clinically interesting compensatory mechanism which might transiently support contractile function during pressure overload before the transition to a decompensated chronic disease. Our data may have direct translational implications for the stage-dependent heart failure therapy using new neprilysin inhibitor drugs, which act by increasing circulating ANP levels.
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Microdomain switch of cGMP-regulated phosphodiesterases leads to ANP-induced augmentation of -adrenoceptor-stimulated contractility in early cardiac hypertrophy 
Detailed Methods
Cloning and transgenic mouse generation. DNA encoding the N-terminal 10 amino acid peptide MGSINSKRKD from the Lyn kinase 1 was subcloned upstream of the start ATG of the Epac1-camps sensor 2 using the HindIII and KpnI restriction sites (the latter resulting in the addition of the additional two amino acids AS), see Online Figure 2A for details. The whole sensor sequence was transferred into the previously described vector containing the MHC promoter and simian virus (SV40) polyadenylation signal. 3 The resulting vector was linearized with SpeI, purified and used for pronuclear injections to generate transgenic mice on the FVB/N background as described. 4 The resultant founder mice and their heterozygote offspring were genotyped by a standard PCR using the primers TGACAGACAGATCCCTCCTAT and CATGGCGGACTTGAAGAAGT, resulting in a ~365 b.p. fragment on a gel.
Histology, morphometric analysis and echocardiography were performed as previously described. 5 For cardiomyocyte dimension analysis, transverse heart sections were incubated with Wheat Germ Agglutinin (WGA, 75 µg/mL) for 30 min in the dark, washed thrice for 5 min with phosphate buffered saline, mounted and observed under Axiovert 200 microscope (Carl Zeiss MicroImaging, Jena, Germany). Images were acquired using AxioVision software (Carl Zeiss MicroImaging) and analyzed with ImageJ software. The cell diameter was measured in 100 cells from 5 sections per heart.
Transverse aortic constriction (TAC). 9-13 week aged female mice were randomized into sham or TAC group. Mice were anesthetized using 1.5-2 % isoflurane in 100 % oxygen. A suprasternal incision was made, and the aortic arch was visualized using a binocular macroscope (Olympus). TAC occurred by spacer defined (26-gauge) constriction using a 6-0 polyviolene suture between the first and second trunk of the aortic arch. 6 For sham, the aorta was exposed but not constricted. 3 days after surgery, Doppler velocity was measured by a 20 MHz probe to quantify the pressure gradient across the TAC region or after sham procedure by transthoracic echocardiography (VisualSonics Vevo 2100; Toronto, Canada). 3 days before and during 1 week after surgery, mice received analgesic therapy with metamizole (1.33 mg/ml in drinking water). Echocardiography was performed 8 weeks after surgery with subsequent heart and cell isolation. The data presented in Online Figure V demonstrate a mild functionally compensated phenotype. The mildness of the phenotype can be explained by the FVB/N1 stain of mice used which is less susceptible to heart failure development after TAC than other mouse strains.
Single-cell contractility measurements. Freshly isolated cardiomyocytes were plated onto laminin-coated glass coverslides. Contractile responses were evaluated by sarcomere length measurements method (IonOptix) at 1 Hz pacing frequency as previously described. 7
In vivo hemodynamic measurements. Recordings of left ventricular pressure volume loops were performed in 1% isoflurane anesthetized mice with a 1.4 F catheter connected to an MPVS Ultra amplifier (Millar Instruments), as previously described 8 . After 10 min of stabilization, mice were infused for 10 min with lactated Ringer's solution at a rate of 0.26 µl/g/min, subsequently 10 min with Isoproterenol at 10 pg/g/min, and finally with a mixture of Isoproterenol (10 pg/g/min) and ANP (500 pg/g/min) in Ringer's solution through the jugular vein. Data were collected and analyzed with a PowerLab 16/30 and Chart 7.3 (ADInstruments).
Confocal microscopy was performed using Zeiss LSM 710 NLO microscope (Carl Zeiss MicroImaging) equipped with a Plan-Apochromat x63/1.40 oil-immersion objective. For live cell imaging, myocytes were incubated with 50 µmol/L of di-8-ANEPPS for 10-15 min. Images were acquired for CFP/YFP (405 nm diode laser excitation) and di-8-ANEPPS (488 nm argon ion laser excitation) and analyzed using ZEN 2010 software (Zeiss). For co-localization experiments, cells were fixed for 20 min with ice-cold ethanol at -20°C, washed and co-stained with mouse monoclonal -actinin antibody (Sigma) and either goat polyclonal anti-PDE2A (sc-17228, Santa Cruz) or goat polyclonal anti-PDE3A (sc-11834, Santa Cruz) antibodies, followed by the secondary anti-mouse Alexa 633 Fluor ® and anti-goat Alexa 488 Fluor ® antibodies (A-21063 and A-11055, respectively, Life Technologies). Images were taken and automatically analyzed using the ZEN 2010 software to calculate the Pearson's coefficient which shows the degree of co-localization. For staining of neonatal rat cardiomyocytes, cells were isolated as previously described 9 and transduced with adenoviruses expressing HA-tagged  1 -AR or FLAG-tagged  2 -AR (kind gift from Dr. Y. K. Xiang) and cultured for 48 h in presence or absence 50 µM phenylephrine (PE) to induce hypertrophy. Thereafter, cells were fixed with methanol/acetone and co-stained with PDE2A/3A and rabbit anti-HA (Covance) or mouse anti-FLAG (Sigma) antibodies for confocal microscopy.
Radioligand binding.
Radioligand binding studies were performed as previously described. 10 Briefly, isolated cell membranes were incubated for 1 h at 30°C with 60-100 pmol/L 125 Icyanopindolol (PerkinElmer Life Sciences, Dreieich, Germany) and increasing concentrations of ICI118551.
Phosphodiesterase activity assay. Freshly isolated cardiomyocytes were lysed and processed for in vitro measurement of cAMP-PDE hydrolyzing activity following the standard method by Thompson and Appleman in presence of 1 µmol/L cAMP as a substrate, as previously described. 11, 12 Contributions of individual PDE families were calculated from the effects of 100 nmol/L BAY (PDE2), 10 µmol/L cilostamide (PDE3), 10 µmol/L rolipram (PDE4), and 100 µmol/L IBMX (unselective inhibitor).
Immunoblot analysis. Freshly isolated cardiomyocytes or heart tissues were shock frozen and homogenized in a buffer containing in mmol/L: 10 HEPES, 300 succrose, 150 NaCl, 1 EGTA, 2 CaCl 2 , and 1 % Triton-X. Proteins were quantified using BCA Protein Assay (Pierce). Samples were boiled at 95°C for 5 minutes, and 10 µg of total protein per lane were subjected to 10 % or 4-12 % (Bis-AA gradient gels, Criterion) SDS-PAGE and to immunoblot analysis using anti-PDE2 antibody (Fabgennix), rabbit polyclonal PDE4D8 antibody (kind gift from Marco Conti), rabbit polyclonal PDE8A antibody (kind gift from George Baillie), goat polyclonal -arrestin 2 antibody (Abcam), rabbit polyclonal PDE3A antibody (kind gift from Chen Yan), rabbit polyclonal AKAP13 antibody (kind gift from Michael Kapiloff), mouse polyclonal PI3K antibody (kind gift from Emilio Hirsch), mouse monoclonal caveolin 3 antibody (Sigma), rabbit polyclonal calsequestrin (Thermo Scientific) and a monoclonal GAPDH antibody (HyTest). To analyze PKA substrate phopshorylation, myocytes isolated from TAC and sham mice were stimulated for 5 min with vehicle, 100 nmol/L ISO or 100 nmol/L ISO plus 100 nmol/L ANP, lysed and subjected to immunoblot analysis using phospho-phospholamban (Ser16, Badrilla) and phospho-myosin binding protein C (Enzo) antibodies. All blots were scanned and analyzed densitometrically by ImageJ software for uncalibrated optical density.
Subcellular fractionation was performed according to the previously described method with minor modifications 13 . Sham and TAC heart lysates were mixed with MES-buffered saline (25 mmol/L MES and 150 mmol/L NaCl, pH=6.5) containing 250 mmol/L Na 2 CO 3 and applied onto sucrose gradient. 10 µg protein from each fraction were loaded onto 4-12 % gradient gel (Bis-AA Criterion) and further processed for immunoblot analysis with the antibodies described above plus  1 -AR (sc-568) and  2 -AR (sc-569) antibodies from Santa Cruz.
cGMP radioimmunoassay. Freshly isolated adult cardiomyocytes from sham and TAC mice were resuspended in IBMX-containing (500 µmol/L) Tyrode's solution. After 15 min the samples were stimulated for 10 min with 100 nmol/L ANP or vehicle, lysed with ethanol and processed for radioimmunoassay analysis as previously described.
14,15
Contraction rate measurements in intact hearts. TAC and sham mice were sacrificed by cervical dislocation. Hearts were rapidly explanted and subjected to Langendorff perfusion with the Krebs-Henseleit solution (in mmol/L: 118 NaCl, 4.7 KCl, 1.2 KH 2 PO 4 , 1.25 MgSO 4 , 24 NaHCO 3 , 1.25 CaCl 2 and 11.1 glucose; constantly oxygenated with 95 % O 2 and 5 % CO 2 ) at 37.5 °C with a constant flow rate of 2.5 ml/min. Heart beats were detected with a custom made electrode and analyzed with Powerlab Chart 5 software (ADInstruments). Hearts were perfused for 3-5 minutes to reach stable baseline and then stimulated with 10 nmol/L ISO for 3-5 min. After reaching the plateau phase, 100 nmol/L of ANP were additionally washed in for another 3-5 min.
Myocardial infaction (MI) model involving left anterior descending coronary artery ligation to induce chronic heart failure in mice was performed exactly as previously described. 5 Operated animals were subjected to echocardiography and subsequent cardiomyocyte isolation 12 weeks post-MI.
Supplemental Figures
Online Figure I . cardiomyocytes. A, Cardiomyocytes were isolated from pmEpac1 mice 12 weeks after myocardial infarction (MI) or sham surgery performed as previously described 5 to induce chronic heart phenotype which was accompanied by ~80% increase in heart-to-body weight ratio, ~60% reduction in factional shortening and a ~45% increase in left-ventricular enddiastolic internal dimension. -not significant at p=0.05. 100 mol/L BAY60-7550 and 10 µmol/L rolipram were used to fully inhibit PDE2 and PDE4, respectively. We also tested whether the cytosolic cAMP levels measured using Epac1-camps may be affected in hypertrophy. In the bulk cytosol, we could also observe similar changes in ANP effects on cAMP levels and an increase in PDE2 contribution after  2 -AR stimulation in TAC myocytes, while changes in PDE3 effects were somewhat less pronounced (Online Figure  XV A Immunoblot analysis of PKA substrate phosphorylation upon ISO and ISO+ANP treatment. Shown are representative immunoblots for phospho-phospholamban (pPLN, Ser16) and phospho-myosin binding protein C (pMyBP-C, Ser282) and quantifications from 3 independent experiments (means ± SE). These data obtained with less sensitive classical biochemical methods show only a tendency for augmented phosphorylation after ANP treatment in TAC cells.
